[1]刘佳 综述 姜玲*审校.糖尿病患者关节置换术围术期血糖控制的研究进展[J].中国微创外科杂志,2021,01(12):1108-1111.
点击复制

糖尿病患者关节置换术围术期血糖控制的研究进展()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2021年12期
页码:
1108-1111
栏目:
临床研究
出版日期:
2021-12-25

文章信息/Info

作者:
刘佳 综述 姜玲*审校
(北京大学第三医院老年内科，北京100191)
文献标志码:
A

参考文献/References:

[1]Na A，Jansky L，Gugala Z. Clinical characteristics of patients with type 2 diabetes mellitus receiving a primary total knee or hip arthroplasty. J Diabetes Res,2019,2019:9459206.
[2]King KB，Rosenthal AK. The adverse effects of diabetes on osteoarthritis: update on clinical evidenceand molecular mechanisms. Osteoarthr Cartilage,2015,23(6):841-850.
[3]聂文波，龚俊.糖尿病患者实施全膝关节置换术的风险及疗效评价.海南医学，2015，26(18):2691-2694.
[4]Blanco JF, Díaz A, Melchor FR, et al. Risk factors for periprosthetic joint infection after total knee arthroplasty. Arch Orthop Traum Surg,2020,140(2):239-245.
[5]American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes-2021. Diabetes Care,2021,44(Suppl 1):S211-S220.
[6]MartínezHuedo MA, JimenezGarcia R, JimenezTrujillo I, et al. Effect of type 2 diabetes on inhospital postoperative complications and mortality after primary total hip and knee arthroplasty. J Arthroplasty,2017,32(12):3729-3734.
[7]Roger C，Debuyzer E，Dehl M，et al. Factors associated with hospital stay length, discharge destination, and 30day readmission rate after primary hip or knee arthroplasty: retrospective cohort study. Orthop Traumatol Surg Res,2019,105(5):949-955.
[8]Kong L，Cao J，Zhang Y，et al. Risk factors for periprosthetic joint infection following primary total hip orknee arthroplasty: a metaanalysis. Int Wound J,2017,14(3):529-536.
[9]Gu A, Wei C, Robinson HN, et al. Postoperative complications and impact of diabetes mellitus severity on revision total knee arthroplasty. J Knee Surg,2020,33(3):228-234.
[10]Cheuy VA, Loyd BJ, Hafner W, et al. Influence of diabetes mellitus on the recovery trajectories of function, strength, and selfreport measures after total knee arthroplasty. Arthrit Care Res,2019,71(8):1059-1067.
[11]Liu P, Liu J, Xia K, et al. Clinical outcome evaluation of primary total knee arthroplasty in patients with diabetes mellitus. Med Sci Monit,2017,23:2198-2202.
[12]Maradit Kremers H, Schleck CD, Lewallen EA, et al. Diabetes mellitus and hyperglycemia and the risk of aseptic loosening in total joint arthroplasty. J Arthroplasty,2017,32(9S):S251-S253.
[13]Kheir MM，Tan TL，Kheir M，et al. Postoperative blood glucose levels predict infection after total joint arthroplasty. J Bone Joint Surg Am,2018,100(16):1423-1431.
[14]Hwang JS, Kim SJ, Bamne AB, et al. Do glycemic markers predict occurrence of complications after total knee arthroplasty in patients with diabetes? Clin Orthop Relat Res,2015,473(5):1726-1731.
[15]Cancienne JM, Brockmeier SF, Werner BC. Association of perioperative glycemic control with deep postoperative infection after shoulder arthroplasty in patients with diabetes. J Am Acad Orthop Surg,2018,26(11):e238-e245.
[16]Tarabichi M，Shohat N，Kheir MM，et al. Determining the threshold for HbA1c as a predictor for adverse outcomes after total joint arthroplasty: a multicenter, retrospective study. J Arthroplasty,2017,32(9):S263-S267.
[17]American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care,2021,44(Suppl 1):S73-S84.
[18]Shohat N，Muhsen K，Gilat R，et al. Inadequate glycemic control is associated with increased surgical site infection in total joint arthroplasty: a systematic review and metaanalysis. J Arthroplasty,2018,33(7):2312-2321.
[19]Garg R，Schuman B，Bader A，et al. Effect of preoperative diabetes management on glycemic control and clinical outcomes after elective surgery. Ann Surg,2018,267(5):858-862.
[20]RodríguezSegade S，Rodríguez J，Camia F. Corrected fructosamine improves both correlation with HbA1c and diagnostic performance. Clin Biochem,2017,50(3):110-115.
[21]Shohat N，Tarabichi M，Tan TL，et al. 2019 John Insall Award: Fructosamine is a better glycaemic marker compared with glycated haemoglobin (HbA1C) in predicting adverse outcomes following total knee arthroplasty: A prospective multicentre study. Bone Joint J,2019,101-B(7_Supple_C): 3-9.
[22]Zheng CM，Ma WY，Wu CC，et al. Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta,2012,413(19-20):1555-1561.
[23]Vellanki P, Rasouli N, Baldwin D, et al. Glycaemic efficacy and safety of linagliptin compared to a basalbolus insulin regimen in patients with type 2 diabetes undergoing noncardiac surgery: A multicentre randomized clinical trial. Diabetes Obes Metab,2019,21(4):837-843.
[24]Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery. Lancet Diabetes Endocrinol,2017,5(2):125-133.
[25]Hulst AH, Visscher MJ, Godfried MB, et al. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: A multicentre randomized superiority trial. Diabetes Obes Metab,2020,22(4):557-565.
[26]Polderman JAW, van Steen SCJ, Thiel B, et al. Perioperative management of patients with type2 diabetes mellitus undergoing noncardiac surgery using liraglutide, glucoseinsulinpotassium infusion or intravenous insulin bolus regimens: A randomised controlled trial. Anaesthesia,2018,73(3):332-339.
[27]Kaneko S, Ueda Y, Tahara Y. GLP1 receptor agonist liraglutide is an effective therapeutic option for perioperative glycemic control in type 2 diabetes within enhanced recovery after surgery (ERAS) protocols. Eur Surg Res,2018,59(5-6):349-360.

备注/Memo

备注/Memo:
*通讯作者，Email：15910776454@163.com
更新日期/Last Update: 2022-04-07